Recent insights into the pathophysiologic underlying mechanisms of obesity have led to the
discovery of several promising drug targets and novel therapeutic strategies to address the …

Stem cell therapies have shown promising therapeutic effects in restoring damaged tissue
and promoting functional repair in a wide range of human diseases. Generations of insulin …

Abstract Aims/Introduction Sodium–glucose cotransporter 2 inhibitors, as well as
thiazolidines, suppress nonalcoholic fatty liver disease (NAFLD); however, few comparative …

Aims Explore the efficacy, safety and tolerability of the dual sodium–glucose cotransporter
(SGLT) 1 and 2 inhibitor, licogliflozin in patients with type‐2 diabetes mellitus (T2DM) and …

The aim of this narrative review is to update the current knowledge on the differential choice
of circulating cardiac biomarkers in patients with prediabetes and established type 2 …

Background: Sodium–glucose cotransporter-2 (SGLT2) inhibitors have proven to be
effective in improving glycemic control in patients with type 2 diabetes mellitus (T2DM) …

Purpose The effect of the sodium-glucose 2 (SGLT-2) inhibitors on microvascular
complications remains uncertain. We performed a systematic review to determine the …

Glucocorticoid-induced hyperglycemia (GIH) is an important complication to be managed by
rheumatologists as it can affect morbidity and mortality of patients. Before administration of …

Aims Sodium-glucose cotransporter-2 inhibitor (SGLT2i) reduces clinic blood pressure (BP),
but the effects on BP circadian rhythm remain unclear. The present study aimed to determine …

A systematic literature review and meta‐analysis was performed to evaluate the effects of
dapagliflozin on low‐density lipoprotein (LDL) cholesterol in type 2 diabetes mellitus. Data …